Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, May 28, 2016 ) Publisher's, 'Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Product Pipeline Review - 2016', provides an overview of the Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4)'s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Other Key Points in Report:
- The report provides a snapshot of the pipeline therapeutic landscape of Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - The report provides overview of Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4)'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4)'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Ask for Sample Report @ www.reportsweb.com/inquiry&RW0001242093/sample
Table of Content: An Overview
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) Overview 6 Therapeutics Development 7 Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Products under Development by Stage of Development 7 Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Products under Development by Therapy Area 8 Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Products under Development by Indication 9 Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Products under Development by Companies 12 Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 17 Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Companies Involved in Therapeutics Development 18 MedImmune, LLC 18
Ask for Discount on Report @ www.reportsweb.com/inquiry&RW0001242093/discount
OncoMed Pharmaceuticals, Inc. 19 PharmAbcine, Inc. 20 Sevion Therapeutics, Inc. 21 Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Drug Profiles 22 demcizumab - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 MEDI-0639 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Monoclonal Antibody to Inhibit DLL4 for Oncology - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Monoclonal Antibody to Inhibit DLL4 for Oncology and Inflammatory Disorders - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 OMP-305B83 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001242093/buy/3500
About Us:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us: Email: sales@reportsweb.com Call: +1-646-491-9876
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
Source: EmailWire.com
|
|
|
|